Clinical trials: Lipid Disorders
Hyper-Triglyceridemia
Effect of Omacor on Triglycerides in HIV Infected Subjects
Omacor is likely to decrease lipid parameters in HIV infected subjects. In these subjects the lipid are decrease due to HAART treatment
- Trial name
- NCT00598910
- Testing
- Omacor
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Solvay Pharmaceuticals
Hypercholesterolemia
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
The purpose of this study was to evaluate the long-term safety and tolerability of ezetimibe 10 mg once daily co-administered with atorvastatin 10 to 80 mg daily for up to 12 consecutive months in participants with heterozygous…
- Trial name
- NCT03882996
- Testing
- Ezetimibe, Atorvastatin
- Volunteers
- 432 people
- Sponsor
- Organon and Co
Dyslipidemia
Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels
The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.
- Trial name
- NCT00749788
- Testing
- JTT-302
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Shionogi Inc.
Dyslipidemia
Observational Study To Evaluate Statins Patterns Of Use In Spain
The present project is aimed at describing the statins prescription pattern in Spanish patients. It will also look into how adequate these prescriptions are accordingly to the recommendations given in Treatment Guidelines and in…
- Trial name
- NCT01023503
- Where
- Spain
- Sponsor
- AstraZeneca
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133146
- Testing
- Grass MATA MPL
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Allergy Therapeutics
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348(3)
- Trial name
- NCT05192356
- Testing
- CKD-348(3), CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
GM1 Gangliosidosis
A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis
LYS-GM101 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the central nervous system.
- Trial name
- NCT04273269
- Testing
- LYS-GM101
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 5 people
- Sponsor
- LYSOGENE
Dry Eye Disease
Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
The purpose of this study is to evaluate the clinical effectiveness and tolerability of SYSTANE® Complete in adult patients with dry eye disease.
- Trial name
- NCT03492541
- Testing
- Propylene glycol-based eye drops
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 134 people
- Sponsor
- Alcon Research
Chronic Smokers, Hyperlipidemia
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate…
- Trial name
- NCT02203227
- Testing
- BioTurmin (Curcuma longa rhizomes extract), BioTurmin-WD (Water dispersible curcuminoids), MaQxan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Olive Lifesciences Pvt Ltd
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Hypercholesterolemia, Coronary Disease
The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe/simvastatin 10/20 mg when administered daily versus doubling the dose of simvastatin to 40 mg in patients with hypercholesterolemia and…
- Trial name
- NCT00423579
- Testing
- Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg
- Volunteers
- 120 people
- Sponsor
- Organon and Co
Mixed Dyslipidemia, Hypercholesterolaemia
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk.
- Trial name
- MEDICI (NCT07614958)
- Where
- United Kingdom
- Volunteers
- 426 people
- Sponsor
- A. Menarini International Licensing S.A.
NAFLD, MASLD
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Dietary intakes of saturated fatty acids remain well above nutritional recommendations for most European countries. This may progressively lead to a pro-inflammatory context and the alteration of lipid metabolism in the liver.
- Conditions
- NAFLD, MASLD, Mild Inflammatory Context
- Trial name
- CnC-TOTUM448 (NCT06047847)
- Testing
- TOTUM-448
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Hypercholesterolemia
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia
The purpose of the study is to determine the reduction of LDL-cholesterol level after treatment with 50 mg per day of lapaquistat acetate once daily (QD).
- Trial name
- NCT00532558
- Testing
- Lapaquistat acetate
- Where
- 60 sites in Estonia, Hungary and 9 more
- Volunteers
- 657 people
- Sponsor
- Takeda
Dyslipidaemia
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
- Trial name
- NCT01632358
- Testing
- TAP311 capsules
- Where
- 3 sites in United States, Jordan and 1 more
- Volunteers
- 279 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolaemia
Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia
The objective of this follow-up retrospective study is to evaluate the long term efficacy and safety of rosuvastatin in reducing lipid parameters in clinical practice.
- Trial name
- NCT01352897
- Where
- Singapore
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Healthy Adult Male and Female Volunteers, Mild Dyslipidemia
EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions.
- Trial name
- NCT07412080
- Testing
- EDP167
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Type II Hyperlipidemia
Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.
- Trial name
- NCT00688896
- Testing
- JTT-705 600 mg and pravastatin 40 mg, JTT-705 300 mg and pravastatin 40 mg
- Where
- Netherlands
- Volunteers
- 155 people
- Sponsor
- Shionogi Inc.
Hyperlipidemias
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
- Trial name
- NCT00813527
- Testing
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Where
- 36 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.